Objectives This study assessed the performances of the Presto CT-NG assay, the Lightmix Kit 480 HT CT/NG and the COBAS Amplicor for Chlamydia trachomatis and Neisseria gonorrhoeae detection.
Design A cross-sectional study design.
Setting Izore, Centre for Diagnosing Infectious Diseases in Friesland, the Netherlands, tested samples sent from regional sexually transmitted infection (STI) outpatient clinics and regional hospitals from the province Friesland, the Netherlands.
Participants Samples were collected from 292 men and 835 women. These samples included 560 urine samples and 567 urethral/cervicovaginal samples.
Primary and secondary outcome measures The primary outcome measure is C trachomatis infection. No secondary outcome measures are available.
Results The sensitivity, specificity, positive predicative value (PPV) and negative predictive value (NPV) for C trachomatis detection in urine samples using the Presto CT-NG assay were 100%, 99.8%, 98.1% and 100%, respectively; for the Lightmix Kit 480 HT CT/NG: 94.2%, 99.8%, 96.1% and 99.4%, respectively; for the COBAS Amplicor: 92.3%, 99.6%, 96% and 99.2%, respectively. The sensitivity, specificity, PPV and NPV for C trachomatis detection in urethral/cervicovaginal swabs using the Presto CT-NG assay and the COBAS Amplicor were 100%, 99.8%, 97.7% and 100%, respectively; for the Lightmix Kit 480 HT CT/NG: 100%, 99.6%, 97.7% and 100%, respectively. Calculations for N gonorrhoeae could not be made due to a low prevalence.
Conclusions All three assays had a high sensitivity, specificity, PPV and NPV for C trachomatis, with best performance for the Presto CT-NG assay.
- Infectious Diseases
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Statistics from Altmetric.com
Strengths and limitations of this study
All CT-NG tests were run at the same time in the same setting reducing potential operator bias.
Although our sample size was quite large, our study had a limited number of Neisseria gonorrhoeae-positive samples, so no sensitivities, specificities, positive predictive values and negative predicting values were calculated.
Three CT/NG tests were used on all available samples using both urine and urethral/cervicovaginal samples.
A slight bias may have been introduced by making use of an alloyed gold standard.
The New CE-IVD marked Presto CT-NG performs equally well as the FDA approved Roche assay.
Urogenital Chlamydia trachomatis and Neisseria gonorrhoeae are the most prevalent bacterial sexually transmitted infections (STIs) in the Netherlands.1 In women, both infections are associated with severe sequelae including pelvic inflammatory disease, tubal scarring and tubal infertility.2 ,3 In Western society, highly sensitive and specific DNA or RNA amplification tests to detect C trachomatis and N gonorrhoeae are commercially available, and have increased detection rates as compared with conventional techniques including culture.4–6 A variety of clinical specimens, that is, urine specimens and cervicovaginal, anorectal or oropharyngeal swabs, can be used for STI detection and cost-saving test strategies have been described.2 ,7 Until recently, the COBAS Amplicor (Roche, California, USA) was the most widely used system for C trachomatis and N gonorrhoeae detection in the Netherlands. Newly developed dual detection systems for C trachomatis and N gonorrhoeae are implemented in Europe in the past 2 years including the Presto CT-NG assay (Goffin Molecular Technologies, Houten, the Netherlands) and the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL, Berlin, Germany).
The aim of this prospective study was to compare the performances of the Presto CT-NG assay, the Lightmix Kit 480 HT CT/NG and the COBAS Amplicor in urine specimens and urethral/cervicovaginal samples for the detection of C trachomatis and N gonorrhoeae in patients visiting general practitioners, gynaecologists and dermatovenereologists for symptoms most commonly generated by an STI.
Materials and methods
Urine specimens (n=560, 238 men and 322 women) and urethral/cervicovaginal swabs (n=567, 54 men and 513 women) were obtained from 292 men and 835 women. Urethral samples were obtained from men only. Samples were sent to Izore for routine STI testing by regional hospitals and general practitioners. Samples were obtained in the period from March to May 2010. An overview of the study design is given in figure 1.
DNA was isolated with MP96 (Roche) according to the manufacturer’s protocol. DNA extraction from the urine samples and swabs for the COBAS Amplicor was performed on the COBAS platform.
C trachomatis and N gonorrhoeae testing
C trachomatis and N gonorrhoeae detection was performed with the Presto CT-NG assay (Goffin Molecular Technologies), the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL) and the COBAS Amplicor (Roche). All tests were performed according to the protocols provided by the respective manufacturers. Owing to cross-reactivity with other Neisseria spp, the COBAS Amplicor-positive results were confirmed with opa PCR. Two qualified technicians performed the tests and were blinded for the results.
Discrepancy analysis and statistical analysis
Samples identified as C trachomatis positive or C trachomatis negative with the Presto CT-NG assay, the Lightmix Kit 480 HT CT/NG and the COBAS Amplicor were defined as true positives and true negatives, respectively, using an alloyed gold standard: If two of three tests were positive, the sample was considered positive. If only one test was positive, the sample was considered negative. The same algorithm was used for N gonorrhoeae.
To calculate the sensitivity, specificity, positive predictive value (PPV) and the negative predictive value (NPV), we used the alloyed gold standard as reference.8 The 95% Wilson Binomial CIs were calculated for the sensitivities, specificities, PPVs and NPVs.9
The overall prevalence for C trachomatis and N gonorrhoeae in this study was 8.1–8.5% and 0.8–0.9%, respectively. Since the number of N gonorrhoeae-positive samples was very limited, we could not reliably calculate sensitivity, specificity, PPV and NPV.
Using the Presto CT-NG assay, C trachomatis DNA was detected in 53 of 560 urine specimens and in 43 of 567 urethral/cervicovaginal specimens, while the Lightmix Kit 480 HT CT/NG and the COBAS Amplicor resulted in 51 and 40, and 50 and 43 C trachomatis positives, respectively. The sensitivity, specificity, PPV and NPV for C trachomatis are summarised in table 1.
For N gonorrhoeae, the Presto CT-NG assay detected 3 of 560 urine specimens and 7 of 567 urethral/cervicovaginal specimens. The Lightmix Kit 480 HT CT/NG and the COBAS Amplicor (followed by opaA confirmation PCR on N gonorrhoeae positives) detected 3 and 7, and 1 and 8 of urine specimens and urethral/cervicovaginal specimens, respectively.
In the Netherlands, the prevalence of STI is stable or slightly increasing.1 Besides education, accurate diagnostics are also essential for prevention of further spreading of STI in the healthy population. Therefore, diagnostic tests, detecting STIs, should display maximum sensitivity whereas false-positives have to be precluded at any time.
We compared the performance of the Presto CT-NG assay (Goffin Molecular Technologies), the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL) and the COBAS Amplicor (Roche) to an alloyed gold standard, defined as a positive result in at least two of three tests. The used samples were urine and urogenital swabs. The results show high specificity, sensitivity, PPV and NPV for all tests, with the Presto CT-NG assay as best overall performance for C trachomatis.
Owing to the low prevalence of N gonorrhoeae, we were not able to calculate specificity, sensitivity, PPV and NPV. The Presto CT-NG assay and the Lightmix Kit 480 HT CT/NG detected N gonorrhoeae equally, but for a definitive validation more samples are needed. The overall prevalence of N gonorrhoeae in this study population was 0.8–0.9%, which is in concordance with a recent report of the National Institute for Public Health and the Environment stating that Friesland province has an N gonorrhoeae prevalence of 1–2%.1 The prevalence of C trachomatis in this study population is slightly lower than the reported annual prevalence: 8.1–8.5% vs 12–14%.1 This observed difference may be explained by the fact that the National Institute for Public Health and the Environment includes data from all STI outpatient clinics in the Netherlands, whereas this study uses samples from a single region.
Performance of the COBAS Amplicor regarding C trachomatis detection in this study was comparable with its performance in other studies.10 ,11 In these other studies, similar high sensitivities, specificities, PPVs and NPVs were achieved, as we found in this study.
To conclude, we find high specificity, sensitivity, PPV and NPV for all tests for C trachomatis, with the Presto CT-NG assay having the best overall performance.
The authors would like to acknowledge Renske Minnema and Griet Verbeek (Izore, Centre for Infectious Diseases Friesland, Leeuwarden, the Netherlands) for the technical support.
TAS and SPV contributed equally.
Contributors TAS was involved in study design, collected and analysed the data. SPV analysed the data and was involved in writing the manuscript. JFLW designed the study, collected the data and critically reviewed the manuscript. SO supervised the data analyses, supervised writing and critically reading of the manuscript. SAM designed the study, was involved in overall supervision and critically reading the manuscript.
Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SAM, employed by the VU University Medical Center has been involved in the technical development of the Presto CT-NG assay (Goffin Molecular Technologies, Houten, the Netherlands) via Microbiome Ltd, a spin-in company of the VU University Medical Center, Amsterdam, the Netherlands.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.